drugset
drugset / Trial / NCT07622004

Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

NCT07622004 ↗

Phase 3 Completed 292 enrolled INIBIO Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.

Timeline

Start
2021-05-27
Primary completion
2022-01-30
Completion
2022-03-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 20 iu —
Subject INI101 Protein / enzyme biologic 20 iu —

Indications

No indication recorded.